MorphoSys (MOR) Given a €125.00 Price Target at Deutsche Bank
Other equities research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. set a €135.00 ($156.98) target price on MorphoSys and gave the stock a buy rating in a research note on Monday, January 28th. Oddo Bhf set a €116.00 ($134.88) target price on MorphoSys and gave the stock a buy rating in a research note on Monday, November 19th. Commerzbank set a €107.00 ($124.42) target price on MorphoSys and gave the stock a neutral rating in a research note on Friday, November 16th. Independent Research set a €104.00 ($120.93) target price on MorphoSys and gave the stock a neutral rating in a research note on Wednesday, November 28th. Finally, Goldman Sachs Group set a €114.00 ($132.56) target price on MorphoSys and gave the stock a neutral rating in a research note on Monday, December 17th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of €101.30 ($117.79).
ETR MOR traded down €1.15 ($1.34) during trading hours on Friday, hitting €85.90 ($99.88). 205,568 shares of the company’s stock were exchanged, compared to its average volume of 153,687. MorphoSys has a 1-year low of €76.45 ($88.90) and a 1-year high of €124.90 ($145.23). The stock has a market capitalization of $2.71 billion and a P/E ratio of -95.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.51 and a quick ratio of 11.21.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.